Professor of Radiology, Cornell University-Weill Medical College
Radiology
Dr. Stanley Goldsmith, MD
|
|
Give Review
Stanley Goldsmith is an expert in the field of Radiology. He graduated from Mount Sinai School of Medicine. He over the years received 5 awards: "America's Top Doctors", "Top Doctors: New York Metro Area", "America's Top Doctors for Cancer", "New York Magazine: Top Doctors" and "Fellow (FACC)". Stanley Goldsmith is also published. He has 55 publications published. The lastest publication: "Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTA-huJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.'
Publications
- Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTA-huJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
- Multiple Myeloma: (18)F-FDG-PET/CT and Diagnostic Imaging.
- 99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metas...
- Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with (131)I-tositumomab.
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer.
- Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis.
- First-in-Man Evaluation of Two High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer.
- Imaging Inflammation in a Patient with Epilepsy Due to Focal Cortical Dysplasia.
- Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
- Early assessment of radiation response using a novel functional imaging modality -- 18Ffluorocholine PET (FCH-PET): a pilot study.
- Rosalyn s. Yalow: a personal and scientific memoir.
- Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents.
- The SNM practice guideline for somatostatin receptor scintigraphy 2.0.
- The Real Cost of Theoretic Risk Avoidance: The Need to Challenge Unsubstantiated Concerns About 131I Therapy.
- To ablate or not to ablate: issues and evidence involved in 131I ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma.
- PET/CT Imaging and Radioimmunotherapy of Prostate Cancer.
- The SNM practice guideline on breast scintigraphy.
- Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year f...
- Radioimmunotherapy of lymphoma: Bexxar and Zevalin.
- Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer.
- PET imaging of leptin biodistribution and metabolism in rodents and primates.
- Clinically proven radiopharmaceuticals for infection imaging: mechanisms and applications.
- Extrathyroidal extension is not all equal: Implications of macroscopic versus microscopic extent in papillary thyroid carcinoma.
- Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
- Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.
- FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease.
- Possible axonal regrowth in late recovery from the minimally conscious state.
- Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
- Subsequent therapy can be administered after tositumomab and iodine I-131 tositumomab for non-Hodgkin lymphoma.
- Lymphoma imaging: nuclear medicine.
- Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lym...
- Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
- Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
- Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
- Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate...
- Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosime...
- PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake.
- Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
- Improving insight into radiobiology and radionuclide therapy.
- Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice.
- Radionuclide imaging of thoracic malignancies.
- The role of FDG-PET imaging in the management of lymphoma.
- PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus.
- Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen.
- Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.
- Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.
- Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human pro...
- Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma.
- Clinical role of FDG PET in evaluation of cancer patients.
- 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma.
- PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
- The utility of monoclonal antibodies in the imaging of prostate cancer.
- Current status of radiolabeled peptides in nuclear medicine diagnosis and therapy.
- Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Schools
University Of Maryland School Of Medicine
Los Angeles Co Genl Hospital
Sinai Hospital Of Baltimore
Doctors Specialties
- Radiology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors: New York Metro Area
- America's Top Doctors for Cancer
- New York Magazine: Top Doctors
- Fellow (FACC)
Education
-
Mount Sinai School of Medicine -
SUNY Health Science Center at Brooklyn -
State University of New York Downstate Medical Center College of Medicine
Hospital
-
NewYork-Presbyterian/Weill Cornell
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1225048994 |
| Last Name Of The Provider | GOLDSMITH |
| First Name Of The Provider | STANLEY |
| View All |
Similar Doctors
|
|
Dr. Elizabeth J. Dubose, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hayden O. Evans III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yuriria S. Lobato, MD |
|
|
Dr. Stuart Mansfield, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laure F. Mazzara, MD
This Doctor is OpenDoctor Recommended.
|